Skip to search formSkip to main contentSkip to account menu

SAR405838

Known as: SAR-405838 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

IndolesSpiro Compoundsp53-HDM2 Interaction Inhibitor MI-773

Narrower (1)

MI-77301

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The Development of New Spirooxindoles Targeting the p53–MDM2 Protein-Protein Interactions for Cancer Therapy
Spiro compounds have drawn ever-increasing attention in drug discovery because of its prevalence in natural products/drugs and… 
2016
2016
Abstract B25: The critical importance of the blood-brain barrier in modulating the response to otherwise highly effective targeted therapies in patient-derived orthotopic glioblastoma xenografts
Clinical data indicate that certain regions within glioblastoma (GBM) have a relatively intact blood-brain barrier (BBB), but… 
2016
2016
Efficacy of the MDM2 inhibitor SAR405838 in PDX models of GBM is limited by active efflux at the BBB
2015
2015
TP53 mutations emerge in circulating cell-free DNA obtained from patients undergoing treatment with the HDM2 antagonist SAR405838.
2515 Background: SAR405838 is an oral antagonist of HDM2 that results in p53 induction. In an ongoing Phase I study, p53… 
2015
2015
303 A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumors
2015
2015
DDEL-15MANIPULATION OF THE BLOOD-BRAIN-BARRIER RESTORES THE EFFICACY OF MDM2 INHIBITION IN ORTHOTOPIC GLIOBLASTOMA MODELS
BACKGROUND: Blood-brain barrier (BBB) integrity is heterogeneous in GBM, and controversy surrounds whether associated… 
2014
2014
379 Identification and rational in silico-based targeting of a novel mediator of metastatic breast cancer
2014
2014
88 Genome-wide drug sensitivity screens in haploid mouse embryonic stem cells
2014
2014
Abstract 1799: Targeted murine double minute 2 (MDM2) inhibition results in dramatic tumor regression in an MDM2-amplified glioblastoma multiforme (GBM) xenograft model
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Disruption of the MDM2/p53 pathway is an oncogenic driver… 
2014
2014
INFLUENCE OF DRUG DELIVERY ON THERAPEUTIC BENEFIT IN GBM–CDK4 AND MDM2 INHIBITOR COMPARISON IN FLANK VERSUS ORTHOTOPIC MODELS AND COMPARISON OF BRAIN PENETRANT VERSUS IMPENETRANT PI3K/MTOR INHIBITORS
BACKGROUND: Insufficient drug delivery across an intact blood-brain barrier (BBB) may limit the efficacy of therapeutic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)